Completed PHASE1 INTERVENTIONAL 5-arm NCT01140607

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment

Sponsor: Sanofi

Conditions Neoplasm Malignant

Interventions Cabazitaxel (XRP6258)

Updated 7 times since 2017 Last updated: Jul 20, 2015 Started: May 31, 2010 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Neoplasm Malignant, this trial is completed. The trial is conducted by Sanofi and has accumulated 7 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Bethlehem, United States , Boston, United States , Canton, United States , Cincinnati, United States , Decatur, United States , Jacksonville, United States , La Jolla, United States , Loma Linda, United States , Metairie, United States and 4 more locations